Indirect Wellbutrin Buyers Denied Cert. Against GSK

Law360, New York (October 7, 2010, 12:51 PM EDT) -- GlaxoSmithKline PLC has escaped a class suit from indirect purchasers of Wellbutrin SR who say the company initiated sham patent litigation to avoid competition, convincing a federal judge the plaintiffs would not have been able to show a predominance of classwide issues.

Judge Lawrence Stengel of the U.S. District Court for the Eastern District of Pennsylvania denied class certification Sept. 30, a major win for GSK, which faces at least two separate putative class actions alleging similar antitrust violations over other drugs.

Judge Stengel spent the...
To view the full article, register now.